Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Wedbush from $48.00 to $50.00. They now have an "outperform" rating on the stock.
Kiniksa Pharmaceuticals Provides Corporate Update
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.